New Lucentis Data Reinforces Profile Across Four Indications


New for Novartis drug ® transformational efficacy and well-established safety

    Pivotal myopic CNV trials with Lucentis® (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year[1]
    New data suggest early treatment initiation with Lucentis results in better vision gains in DME patients[2]
    Meta-analysis of 14 trials and 6504 patients confirms well-established Lucentis safety profile reported from real-world experience and extensive clinical trials[3]

Basel, September 27, 2013 – New clinical and real world data for Lucentis® (ranibizumab) presented in over 40 abstracts at this week’s EURETINA congress confirm its transformational and well-established safety profile in four retinal diseases. Designed for intraocular use, Lucentis is an antibody fragment with a short systemic half-life and was first launched in Europe in 2007. Lucentis is now indicated in many countries for the treatment of wet age-related macular degeneration (wet AMD), for visual impairment due to diabetic macular edema (DME), macular edema secondary to branch- and central-retinal vein occlusion (BRVO and CRVO), and choroidal neovascularization secondary to pathologic myopia (myopic CNV).

“The abundance and quality of new data presented at EURETINA, in addition to the real-world long-term experience with Lucentis, speak to the importance of this anti-VEGF treatment for providing vision gains to patients and affirms its role as the standard of care in retinal medicine,” said Dr Timothy Wright, Global Head Development, Novartis Pharmaceuticals. “Further to its transformational patient outcomes in wet AMD, DME, and RVO, Lucentis has now established its superior efficacy in myopic CNV compared with verteporfin photodynamic therapy as well.”

Lucentis study highlights at the 13th European Society of Retina Specialists (EURETINA) Congress in…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS